Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How to select targeted therapy in renal cell cancer.
Escudier B, Albiges L, Blesius A, Loriot Y, Massard C, Fizazi K. Escudier B, et al. Among authors: blesius a. Ann Oncol. 2010 Oct;21 Suppl 7:vii59-62. doi: 10.1093/annonc/mdq371. Ann Oncol. 2010. PMID: 20943644 Free article. Review.
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Blesius A, Beuselinck B, Chevreau C, Ravaud A, Rolland F, Oudard S, Escudier B. Blesius A, et al. Clin Genitourin Cancer. 2013 Jun;11(2):128-33. doi: 10.1016/j.clgc.2012.12.001. Epub 2013 Jan 17. Clin Genitourin Cancer. 2013. PMID: 23332872 Clinical Trial.
[New drugs in metastatic castration-resistant prostate cancer].
Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K. Albiges L, et al. Among authors: blesius a. Bull Cancer. 2010 Jan;97(1):149-59. doi: 10.1684/bdc.2009.1023. Bull Cancer. 2010. PMID: 20022854 French.
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Adenis A, Blay JY, Bui-Nguyen B, Bouché O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blésius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A. Adenis A, et al. Among authors: blesius a. Ann Oncol. 2014 Sep;25(9):1762-1769. doi: 10.1093/annonc/mdu237. Epub 2014 Jul 25. Ann Oncol. 2014. PMID: 25122671 Free PMC article. Clinical Trial.
Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.
Ciccolini J, Dahan L, André N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz JF, Mercier C. Ciccolini J, et al. Among authors: blesius a. J Clin Oncol. 2010 Jan 1;28(1):160-5. doi: 10.1200/JCO.2009.24.4491. Epub 2009 Nov 23. J Clin Oncol. 2010. PMID: 19933910
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, Varoquaux A, Frances N, Marouani H, Giovanni A, Ferri-Dessens RM, Chefrour M, Favre R, Duffaud F, Seitz JF, Zanaret M, Lacarelle B, Mercier C. Yang CG, et al. Among authors: blesius a. Cancer Chemother Pharmacol. 2011 Jan;67(1):49-56. doi: 10.1007/s00280-010-1282-4. Epub 2010 Mar 5. Cancer Chemother Pharmacol. 2011. PMID: 20204365 Clinical Trial.
20 results